Cargando…

Monitoring of minimal residual cancer in bone marrow in high-risk breast cancer patients treated with high-dose chemotherapy

Detalles Bibliográficos
Autores principales:	Drageset, V, Nesland, JM, Erikstein, B, Skovlund, E, Sommer, H, Anker, G, Wist, E, Lundgren, S, Bergh, J, Kvalheim, G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2005
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4233606/ http://dx.doi.org/10.1186/bcr1185

Ejemplares similares

HER-2 activation and TP53 inactivation as predictors of survival in breast cancer
por: Andersen, TI, et al.
Publicado: (2000)

Screening breast cancer patients for Norwegian ATM mutations
por: Laake, K, et al.
Publicado: (2000)

Screening breast cancer patients for Norwegian ATM mutations
por: Laake, K, et al.
Publicado: (2000)

Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival
por: Mathiesen, Randi R, et al.
Publicado: (2012)

Minimal residual disease (MRD) in the bone marrow in ER-α-positive primary breast cancer patients
por: Coombes, RC, et al.
Publicado: (2005)

Clinical impact of minimal residual disease in blood and bone marrow of children with acute myeloid leukemia
por: Karol, Seth E., et al.
Publicado: (2023)

Treatment Strategy for Ultra-High-Risk Multiple Myelomas with Chromosomal Aberrations Considering Minimal Residual Disease Status and Bone Marrow Microenvironment
por: Suzuki, Kazuhito, et al.
Publicado: (2023)

Ultrasound assessment of residual abnormalities following primary chemotherapy for breast cancer.
por: Seymour, M. T., et al.
Publicado: (1997)

Weekly Paclitaxel plus Capecitabine versus Docetaxel Every 3 Weeks plus Capecitabine in Metastatic Breast Cancer
por: Wist, E. A., et al.
Publicado: (2012)

Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
por: Mohan, Meera, et al.
Publicado: (2022)

Minimal residual disease in high-risk neuroblastoma shows a dynamic and disease burden-dependent correlation between bone marrow and peripheral blood
por: Lin, Kyaw San, et al.
Publicado: (2021)

Pharmacokinetics of mitoxantrone in cancer patients treated by high-dose chemotherapy and autologous bone marrow transplantation.
por: Richard, B., et al.
Publicado: (1992)

Prostate Cancer Cell Lines under Hypoxia Exhibit Greater Stem-Like Properties
por: Ma, Yuanyuan, et al.
Publicado: (2011)

Synergistic effect of SCF and G-CSF on stem-like properties in prostate cancer cell lines
por: Ma, Yuanyuan, et al.
Publicado: (2012)

Computing with Residue Numbers in High-Dimensional Representation
por: Kymn, Christopher J., et al.
Publicado: (2023)

Molecular Detection of Minimal Residual Cancer in Surgical Margins of Head and Neck Cancer Patients
por: Graveland, A. Peggy, et al.
Publicado: (2009)

Flow Cytometric Analysis of Bone Marrow Particle Cells for Measuring Minimal Residual Disease in Multiple Myeloma
por: Jiang, Duanfeng, et al.
Publicado: (2022)

Minimal residual disease and circulating tumor cells in breast cancer
por: Ignatiadis, Michail, et al.
Publicado: (2011)

Impact of obesity on breast cancer recurrence and minimal residual disease
por: Ecker, Brett L., et al.
Publicado: (2019)

Cancer Special Issue: Early detection and minimal residual disease
por: Odeny, Beryne
Publicado: (2021)

Metabolic memory underlying minimal residual disease in breast cancer
por: Radic Shechter, Ksenija, et al.
Publicado: (2021)

Minimal residual disease in breast cancer: an overview of circulating and disseminated tumour cells
por: Tachtsidis, A., et al.
Publicado: (2016)

Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma
por: Flores-Montero, J, et al.
Publicado: (2017)

Tumour microvessel density as predictor of chemotherapy response in breast cancer patients
por: Tynninen, O, et al.
Publicado: (2002)

High-dose chemotherapy and autologous bone marrow transplantation for patients with poor prognosis nonseminomatous germ cell tumours.
por: Barnett, M. J., et al.
Publicado: (1993)

Post-chemotherapy Changes in Bone Marrow in Acute Leukemia With Emphasis on Detection of Residual Disease by Immunohistochemistry
por: Ayyanar, Pavithra, et al.
Publicado: (2021)

Survival of patients with advanced urothelial cancer treated with cisplatin-based chemotherapy.
por: Fosså, S. D., et al.
Publicado: (1996)

Demonstration of highly specific toxicity of the α-emitting radioimmunoconjugate(211)At-rituximab against non-Hodgkin's lymphoma cells
por: Aurlien, E, et al.
Publicado: (2000)

B-Cell Regeneration Profile and Minimal Residual Disease Status in Bone Marrow of Treated Multiple Myeloma Patients
por: Mendonça de Pontes, Robéria, et al.
Publicado: (2021)

High-intensity exercise during chemotherapy induces beneficial effects 12 months into breast cancer survivorship
por: Mijwel, Sara, et al.
Publicado: (2019)

High dose chemotherapy and autologous bone marrow transplantation in refractory Hodgkin's disease.
por: Philip, T., et al.
Publicado: (1986)

Highly favorable physiological responses to concurrent resistance and high-intensity interval training during chemotherapy: the OptiTrain breast cancer trial
por: Mijwel, Sara, et al.
Publicado: (2018)

Subclinical cardiotoxicity following adjuvant dose-escalated FEC, high-dose chemotherapy, or CMF in breast cancer
por: Erselcan, T, et al.
Publicado: (2000)

Immunocytochemical assessment of bone marrow aspirates for monitoring response to chemotherapy in small-cell lung cancer patients
por: Pelosi, G, et al.
Publicado: (1999)

Prognostic value of genomic alterations in minimal residual cancer cells purified from the blood of breast cancer patients
por: Austrup, F, et al.
Publicado: (2000)

Standardized assay for assessment of minimal residual disease in blood, bone marrow and apheresis from patients with plasma cell myeloma
por: Blum, Agnieszka, et al.
Publicado: (2019)

Circulating Tumor DNA Using Tagged Targeted Deep Sequencing to Assess Minimal Residual Disease in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
por: Cirmena, Gabriella, et al.
Publicado: (2020)

Concurrent chemotherapy and radiotherapy in invasive cervical cancer patients with high risk factors.
por: Park, T. K., et al.
Publicado: (2000)

Next-generation sequencing in the diagnosis and minimal residual disease assessment of acute myeloid leukemia
por: Levine, Ross L., et al.
Publicado: (2019)

Effects of intensive induction and consolidation chemotherapy with idarubicin and high dose cytarabine on minimal residual disease levels in newly diagnosed adult precursor-B acute lymphoblastic leukemia()
por: Bradstock, Kenneth F., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_0l8rbp8q3pr5rci5o1ogtt8l77